Drugs / JMKX003142
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07565441 | May → Nov 2026 expected | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07470177 | Mar → May 2026 overdue | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07463053 | Mar → May 2026 overdue | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06658964 | Nov → Dec 2024 overdue | autosomal dominant polycystic kidney disease | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06344533 | Apr 2024 → Jan 2025 | — | Jemincare | Unknown | No outcome recorded |
| Phase 1 | NCT06079541 | Jul 2023 → Jul 2024 | — | Jemincare | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06949020 | Jun 2025 → Jan 2027 expected | heart failure | Jemincare | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06800651 | Mar 2025 → Feb 2027 expected | autosomal dominant polycystic kidney disease | Jemincare | Recruiting | No outcome recorded |
| Phase 2 | NCT06670534 | Jan 2025 → Jul 2026 overdue | — | Jemincare | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JMKX003142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06658964 ↗ |
| Action | Inhibit | “JMKX003142 is an arginine vasopressin（AVP）-V2R antagonist” NCT06670534 ↗ |
| Route | Oral | “JMKX003142 will be administered orally” NCT06079541 ↗ |